Research To Practice | Oncology Videos

Latest Episodes:

Colorectal Cancer | Pashtoon M Kasi, MD, MS May 09, 2023

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Colorectal Cancer Faculty Presentation 2: Other Therapeutic Considerations in CRC — Dr Pashtoon M Kasi

CME information and select publications

Colorectal Cancer | Wells A Messersmith, MD May 09, 2023

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Colorectal Cancer Faculty Presentation 1: Targeted Therapy for Colorectal Cancer (CRC) — Dr Wells A Messersmith

CME information and select publications

Colorectal Cancer | Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Colorectal Cancer May 09, 2023

Show notes

Featuring perspectives from Drs Pashtoon M Kasi and Wells A Messersmith, including the following topics:

Introduction (0:00)
Overview of Endometrial Cancer (9:50)
Management of Microsatellite Instability-High Endometrial Cancer (23:40)
Management of Microsatellite-Stable Endometrial Cancer (33:32)
Clinical Trials in Endometrial Cancer (50:04)
Systemic Therapy for Cervical Cancer — Immunotherapy (1:03:44)
Antibody-Drug Conjugates for Cervical Cancer — Tisotumab Vedotin (1:16:01)

CME information and select publications

Prostate Cancer | Oncology Today: Recent Research Advances in Prostate Cancer and the Clinical Implications – A 2023 Post-ASCO GU Activity May 05, 2023

Show notes

Featuring perspectives from Drs Andrew J Armstrong and Rana R McKay, including the following topics:

Introduction (0:00)
Intensification of endocrine therapy: Emerging role in nonmetastatic disease; choice of androgen deprivation therapy (3:31)
Management of castration-resistant M0 disease; PROTACs, CDK4/6 inhibitors and other new endocrine approaches (16:18)
Hormone-sensitive metastatic disease — Choice of antiandrogen (26:48)
Castration-resistant metastatic disease (37:06)
Genomic evaluation; PARP inhibitors for metastatic disease (46:24)
Ideal sequencing of PARP inhibitors; management of associated side effects (55:21)
Biomarker testing; MSI-high disease; TKIs with immunotherapy; bispecific antibodies? (59:42)

CME information and select publications

Prostate Cancer | Daniel P Petrylak, MD May 05, 2023

Show notes

Oncology Today: Recent Research Advances in Prostate Cancer and the Clinical Implications – A 2023 Post-ASCO GU Activity — Faculty Presentation: Dr Daniel Petrylak

Visit our website for more publications

Non-Small Cell Lung Cancer | Luis Paz-Ares, MD, PhD May 01, 2023

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer — Faculty Presentation 2: Advances in the Care of Patients with Nonmetastatic NSCLC and Small Cell Lung Cancer — Dr Luis Paz-Ares

CME information and select publications

Non-Small Cell Lung Cancer | Heather Wakelee, MD May 01, 2023

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer — Faculty Presentation 1: Management of Metastatic Non-Small Cell Lung Cancer (NSCLC) without an Actionable Mutation — Dr Heather Wakelee

CME information and select publications

Lung Cancer | Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer May 01, 2023

Show notes

Featuring perspectives from Drs Luis Paz-Ares and Heather Wakelee, including the following topics:

Introduction: Looking Back at Immuno-oncology Therapies (0:00)
Metastatic Disease (7:46)
Localized Non-Small Cell Lung Cancer (42:16)
Small Cell Lung Cancer (59:48)

CME information and select publications

Meet The Professor: Optimizing the Management of ER-Positive and Triple-Negative Breast Cancer — Part 3 Apr 27, 2023

Show notes

Featuring perspectives from Dr Sara A Hurvitz, including the following topics:

Introduction: Antibody-Drug Conjugates in Breast Cancer (0:00)
Case: A premenopausal woman in her late 40s with 0.8-cm ER/PR-positive, HER2-negative invasive ductal carcinoma (IDC) with 2 positive nodes and an Oncotype DX® Recurrence Score® (RS) of 9 — Ranju Gupta, MD (13:59)
Case: A premenopausal woman in her early 40s with 5-cm ER/PR-positive, HER2-negative Grade I IDC — Nick Leasure, MD (17:43)
Case: A woman in her early 70s with ER/PR-positive, HER2-low (IHC 1+) metastatic IDC receiving T-DXd with mixed response — Gigi Chen, MD (38:38)
Case: A woman in her late 40s with multicentric triple-negative breast cancer with a gBRCA1 mutation who receives treatment per KEYNOTE-522 and achieves a complete remission with neoadjuvant treatment — Zanetta S Lamar, MD (44:27)
Case: A premenopausal woman in her early 50s with bilateral ER/PR-positive, HER2-negative, IDC with PALB2 mutation and multiple, bilateral positive nodes — William R Mitchell, MD (46:44)
Case: A woman in her mid 30s who is 18 weeks pregnant and is diagnosed with ER/PR-positive, HER2-negative IDC and an Oncotype DX RS of 17 — Alan B Astrow, MD (50:48)
Case: A woman in her late 40s with ER/PR-positive, HER2-negative metastatic breast cancer with NTRK mutation and CNS involvement who receives entrectinib — Rahul Gosain, MD (52:55)
Case: A woman in her early 60s with ER/PR-positive, HER2-negative metaplastic breast cancer with an Oncotype DX RS of 51 who has received an adjuvant aromatase inhibitor for 16 years — Rajalaxmi McKenna, MD (56:04)

CME information and select publications

Endometrial Cancer | Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Endometrial Cancer Apr 26, 2023

Show notes

Featuring perspectives from Drs Robert L Coleman, Matthew A Powell and Brian M Slomovitz, moderated by Dr Shannon N Westin, including the following topics:

Immune Checkpoint Inhibitors for Patients with Advanced Microsatellite Instability (MSI)-High/Mismatch Repair (MMR)-Deficient Endometrial Cancer — Dr Powell
- Introduction (0:00)
- Case: A woman in her early 60s with MSI-high recurrent endometrioid adenocarcinoma of the uterus experiences progression after minimal response to carboplatin/paclitaxel — Lyndsay J Willmott, MD (2:25)
- Case: A woman in her early 50s with MSI-high metastatic endometrial adenocarcinoma after rapid, highly symptomatic progressive disease on paclitaxel/carboplatin — Kellie E Schneider, MD (8:21)
- Faculty presentation: Dr Powell (14:35)
Immunotherapy-Based Strategies for Patients with MMR-Proficient (pMMR) Endometrial Cancer — Dr Coleman
- Case: A woman in her early 60s with a 10-cm right ovarian mass and right pelvic adenopathy; total abdominal hysterectomy with bilateral salpingo-oophorectomy and para-aortic lymph node dissection reveal microsatellite stable (MSS) carcinosarcoma of the endometrium with right ovary and pelvic lymph node involvement (R0); adjuvant paclitaxel/carboplatin administered — Thomas P Morrissey, MD (24:46)
- Case: A woman in her late 60s with Stage IB, Grade 1 endometrial cancer after hysterectomy/sentinel lymph node biopsy — Dana M Chase, MD (30:11)
- Faculty presentation: Dr Coleman (35:54)
Diagnosis and Management of Adverse Events Associated with Immune Checkpoint Inhibitors Alone and in Combination for Endometrial Cancer — Dr Westin
- Case: A woman in her early 60s with a family history of breast cancer — Dr Morrissey (46:05)
- Case: A woman in her mid 70s who underwent hysterectomy, lymphadenectomy, omentectomy and 6 cycles of carboplatin/paclitaxel for a Stage IB MSS serous endometrial cancer; develops metastatic disease to the lungs 11 months later and is started on lenvatinib/pembrolizumab — Dr Chase (51:36)
- Faculty presentation: Dr Westin (57:09)
Novel Investigational Agents and Strategies Under Evaluation for Patients with Endometrial Cancer — Dr Slomovitz
- Case: A woman in her early 70s with HER2-positive serous carcinoma of the uterus receives adjuvant carboplatin/paclitaxel and trastuzumab, now no evidence of disease and receiving maintenance trastuzumab — Dr Willmott (1:07:34)
- Case: A woman in her early 80s with MSI-high metastatic endometrial cancer who receives talazoparib on the TAPUR clinical trial after experiencing progressive disease on pembrolizumab after 4 cycles — John K Chan, MD (1:13:01)
- Faculty presentation: Dr Slomovitz (1:18:53)